News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,726 Results
Type
Article (40912)
Company Profile (267)
Press Release (680537)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204668)
Career Advice (2023)
Deals (35533)
Drug Delivery (110)
Drug Development (81386)
Employer Resources (173)
FDA (16412)
Job Trends (14945)
News (346389)
Policy (32727)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2567)
Accelerated approval (33)
Adcomms (24)
Allergies (142)
Alliances (49576)
ALS (169)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (310)
Approvals (16679)
Artificial intelligence (514)
Autoimmune disease (155)
Automation (39)
Bankruptcy (361)
Best Places to Work (11637)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (638)
Cancer (4800)
Cardiovascular disease (398)
Career advice (1708)
Career pathing (36)
CAR-T (282)
CDC (44)
Celiac Disease (2)
Cell therapy (743)
Cervical cancer (36)
Clinical research (69567)
Collaboration (1700)
Company closure (4)
Compensation (1162)
Complete response letters (55)
COVID-19 (2710)
CRISPR (89)
C-suite (843)
Cystic fibrosis (143)
Data (6224)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6687)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (253)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90172)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117273)
Executive appointments (972)
FDA (19524)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1466)
Gene editing (195)
Generative AI (43)
Gene therapy (595)
GLP-1 (966)
Government (4659)
Grass and pollen (6)
Guidances (383)
Healthcare (18872)
HIV (58)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (2980)
Inflammatory bowel disease (188)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (249)
Interviews (315)
IPO (16642)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (546)
Leadership (31)
Legal (7949)
Liver cancer (91)
Longevity (14)
Lung cancer (647)
Lymphoma (376)
Machine learning (42)
Management (59)
Manufacturing (792)
MASH (163)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19961)
Metabolic disorders (1266)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (315)
Neuropsychiatric disorders (88)
Neuroscience (2894)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4514)
Now hiring (67)
Obesity (594)
Opinion (258)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (226)
Parkinson's disease (280)
Partnered (33)
Patents (495)
Patient recruitment (489)
Peanut (56)
People (58865)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21685)
Phase 2 (30616)
Phase 3 (22814)
Pipeline (5277)
Policy (282)
Postmarket research (2564)
Preclinical (9197)
Press Release (64)
Prostate cancer (237)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (833)
Real estate (5954)
Recruiting (70)
Regulatory (24484)
Reports (52)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (78)
Schizophrenia (148)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (96)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (1004)
Venture capital (88)
Weight loss (380)
Women's health (91)
Worklife (18)
Date
Today (29)
Last 7 days (580)
Last 30 days (2016)
Last 365 days (29786)
2026 (3450)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51175)
2021 (55711)
2020 (54083)
2019 (46540)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39225)
Australia (6409)
California (11287)
Canada (3286)
China (1100)
Colorado (477)
Connecticut (476)
Delaware (336)
Europe (84518)
Florida (1689)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (430)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1381)
Massachusetts (8081)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (3000)
New Mexico (28)
New York (2973)
North Carolina (1449)
North Dakota (8)
Northern California (5516)
Ohio (333)
Oklahoma (21)
Oregon (41)
Pennsylvania (2278)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4392)
Tennessee (174)
Texas (1740)
United States (39992)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
721,726 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Press Releases
Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.
February 10, 2026
·
2 min read
Press Releases
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
February 12, 2026
·
5 min read
Press Releases
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2026
·
4 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
1 of 72,173
Next
